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Background: Current knowledge about the molecular properties and prognostic markers of upper tract urothelial
carcinoma (UTUC) is sparse and often based on bladder urothelial carcinoma (UC), which is thought to share common
risk factors with UTUC. However, studies have suggested that differences exist regarding tumor behavior and molecular
biology of these cancers, comprehensive investigations are needed to guide the clinical management of UTUC. In
recent years, massively parallel sequencing has allowed insights into the biology of many cancers, and molecular
prognostic markers based on this approach are rapidly emerging. The goal of this study was to characterize the gene
expression patterns of UTUC using massively parallel sequencing, and identify potential molecular markers for
prognosis in patients with UTUC.
Methods: We compared the genome-wide mRNA expression profile of cancer and matched normal tissues from 10
patients with UTUC to identify significantly deregulated genes. We also examined the protein levels of prognostic
marker candidates in 103 patients with UTUC, and tested the association of these markers with overall survival using
Kaplan-Meier model and Cox regression.
Results: Functional enrichment of significantly deregulated genes revealed that expression patterns of UTUC were
characterized by disorders of cell proliferation and metabolism. And we also compared the expression profile of UTUC
with that of bladder UC. Our results highlighted both shared (e.g. disorders of cell cycling and growth signal
transduction) and tumor-specific (e.g. abnormal metabolism in UTUC and disruptions of adhesion pathways in bladder
UC) features of these two cancers. Importantly, we identified that low protein expression of ALDH2 while high CCNE1
and SMAD3 were significantly associated with increased depth (*P <0.05) and lower overall survival (***P <0.0001) in an
independent set of 103 patients. Multivariate Cox regression revealed that all these three genes were independent
prognostic indicators in patients with UTUC (***P <0.001).
Conclusions: In conclusion, our study characterized the comprehensive expression profile of UTUC and highlighted
both commons and differences in expression patterns between UTUC and bladder UC. And we, for the first time,
revealed that ALDH2, CCNE1 and SMAD3 are associated with prognosis in patients with UTUC.
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UTUC of renal pelvis is relatively rare, but aggressive
type of kidney cancer with high recurrence rates. It com-
prises of ~8.4% of histologically confirmed cancers in
kidney and approximately 5% of all urothelial neoplasms
[1,2]. Current knowledge about the molecular basis of
UTUC is sparse and often based on bladder UC, which
is the predominant subtype of UC and thought to share
common risk factors with UTUC like cigarette smoking
and use of phenacetin-containing analgesics [2,3]. How-
ever, studies have suggested that differences exist regard-
ing tumor location and behavior between the upper and
the lower urinary tract [4-6]. In addition, Catto et al.
showed that distinct patterns of microsatellite instability
and promoter methylation occur in these cancers [7,8],
comprehensive studies therefore are needed to guide the
clinical managements of UTUC. Until recently, most of
the efforts for identifying prognostic indicators focused
on only a few pre-selected genes, tumor stage and grade
still represent the best-established prognostic indicators
in patients with UTUC [3,4]. It is of paramount import-
ance to increase our understanding of the molecular
basis like disrupted pathways of this cancer to refine the
clinical decision-making process. In recent years, massive
expression profiling techniques such as microarray and
next-generation sequencing has allowed comprehensive
insights into both the biology and clinical aspect of many
cancers, and molecular prognostic markers based on this
approach are rapidly emerging [9-11]. Compared to mi-
croarrays, sequence-based profiling does not suffer from
cross-hybridization of mRNA sequences and has higher
reproducibility, and it can achieves the measurement of
gene expression level with unlimited dynamic range [12].
Here, using massively parallel sequencing, we com-
pared the expression patterns of UTUCs and matched
normal controls aiming to characterize the mRNAs
spectra as well as identify potential molecular prognostic
markers of this cancer. We identified that the expression
patterns of UTUC were characterized by disorders of
cell proliferation and metabolism. And we revealed that
UTUC and bladder UC shared common molecular fea-
tures (e.g. disorders of cell cycling and growth signal
transduction), while they also have tumor-specific fea-
tures (e.g. abnormal metabolism in UTUC and disrup-
tions of adhesion pathways in bladder UC). Importantly,
we identified that low protein expression of ALDH2
while high CCNE1 and SMAD3 were novel independent
predictors of adverse outcome in patients with UTUC.
Methods
Sample collection
Written informed consents were obtained from all the
10 patients with UTUC of renal pelvis, and this study
was approved by the institutional review board of SunYat-sen University (Guangzhou, China). None of the pa-
tients in this study underwent radiotherapy or chemo-
therapy before surgery. Histological examination and
clinical diagnosis of the tumorous and normal adjacent
tissues from renal pelvis in patients were performed by
the Cancer Center of Sun Yat-sen University. Fresh tis-
sues were immediately immersed in RNAlater (Qiagen;
Germany) after surgical resection and stored at 4°C
overnight to allow thorough penetration of the tissues,
which were thereafter stored at −80°C. Hematoxylin-
eosin (HE) staining were performed to examine the per-
centage of tumor cells, and tumor tissues containing
more than 80% tumor cells were selected for further in-
vestigation. We also confirmed using histopathologic
examination that the normal tissue did not contain any
cancer cells. The disease stage of each patient was classi-
fied according to the 2002 American Joint Committee on
Cancer (AJCC) staging system. Information on all these
patients is summarized in Additional file 1: Table S1.
Gene expression profiling using digital gene expression
sequencing
Library construction of digital gene expression sequen-
cing (DGE; BGI-Shenzhen, China) generates tags with
21 base pairs (bp) from the 3’ ends of each transcript,
and such tags are utilized to represent the expression
levels of transcripts [12]. Sequencing libraries were pre-
pared as before [13]. In brief, after extraction of total
RNA, we synthesized double-stranded cDNA from RNA
using oligo (dT)18 beads (Invitrogen, US). Afterwards,
cDNA product was digested with NlaIII and then linked
to first sequencing adapter. The product of ligation was
digested with MmeI and linked to the second adapter.
Then, the double adapter-flanked tags were amplified
and products were purified using Spin-X filter columns.
Finally, mRNA libraries were sequenced on the Illumina
Genome Analyzer II (Illumina Inc, US) system following
the manufacturer’s protocol. The expression profiling
dataset was submitted to Gene Expression Omnibus
(GEO) under the accession number of GSE47702.
Analyses of sequencing data
Details of primary analyses of DGE sequencing data
were described before [13]. In brief, all of the 17-bp
DNA sequences next to the NlaIII restriction sites on
human reference genome (hg19) along with the 4-bp
CATG recognition site were extracted and concatenated
as a new reference [14]. Tags were mapped to the con-
structed reference using SOAP2 allowing no more than
one mismatch [15]. Normalized TPM (transcripts per
million clean tags) values and fold change (absolute
value of log2ratio, cancer versus normal) were calculated
using uniquely mapping tags. Subsequently, candidates
of differentially expressed genes were determined using
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which a p-value for each gene was calculated for each of
the 10 cancer-normal pairs [16]. We then calculated the
false discovery rate (FDR) to control the proportion of
false positive results [17]. For the comparison with micro-
array data, we used Venny (http://bioinfogp.cnb.csic.es/
tools/venny/) to generate the Venn diagram, and statistical
significance of overlapping was calculated using hypergeo-
metric test by R (http://www.R-project.org). A two-way
unsupervised hierarchical clustering was done using aver-
age linkage and uncentered Pearson correlation metric by
Gene Cluster 3.0, and results were visualized using Tree-
View [18].
For pathway enrichment, we took all the recurrently
deregulated genes as input for Cytoscape with ClueGO
plug-in [19,20]. To mine out the cancer relevant genes,
we performed leading edge analysis of gene set enrich-
ment (GSEA) analysis tool [21]. Core genes ranked at
the both ends on the heat map of each gene set were
most significantly discrepant between tumorous and
matched normal tissues. In our study, all the deregulated
genes were interrogated in the gene sets of ‘Pathway in
cancer’ (hsa05200) curated by KEGG and ‘Cancer mo-
lecular’ in MSigDB database [21,22]. Besides, we per-
formed GeneMANIA analysis to search genes that have
co-expression, physical interaction, pathway relationship
and shared protein domain with ALDH2, CCNE1 and
SMAD3 [23].
qPCR
Ten genes with wide range of fold change (−11.4 to 4.5)
were selected for technical validation to check the reli-
ability of the analytical methods for detecting differen-
tially expressed genes with various fold changes. As
described [13], we performed qPCR testing the expres-
sions of these 10 genes in both cancer and matched nor-
mal tissues of the 10 patients in discovery screen. The
expression level of each gene was normalized with U6 as
it was highly expressed and stable in our samples. Value
of ΔCt = Ct-gene - Ct-U6 was calculated for each gene. All
the primers are listed in Additional file 1: Table S2.
Immunohistochemistry scoring and survival analysis
Immunohistochemistry (IHC) assay was performed as
described before [24]. Formalin-fixed paraffin-embedded
(FFPE) sections after IHC staining were reviewed for the
degree of immunostaining and scored by 2 independent
observers based on the proportion of protein-expressing
tumor cells: 0, no positive cells; 1, <5%; 2, 6%-25%; 3,
26%-50%; 4, 51%-75%; and 5, >75%. The staining inten-
sity was graded according to the mean optical density: 0,
no staining; 1, weak staining (light yellow); 2, moderate
staining (yellow brown); and 3, strong staining (brown).
We utilized proportion of protein-expressing cancercells and staining intensity to calculate the staining index
representing the protein expression.
We dichotomized the patient cohort based on the pro-
tein expression of ALDH2, CCNE1 and SMAD3: high-
expression groups with staining index score of ≥ five and
low-expression group withs score of ≤ four. Fisher’s exact
test and chi-square test were performed using GraphPad
Prism 6 where appropriate to test the correlation be-
tween protein expression and clinicopathologic variables.
Besides, to examine the association between expression
and prognosis, survival curves were estimated using the
Kaplan-Meier model carried out by GraphPad Prism 6,
and curves were compared using the log-rank test. We
also performed multivariate (i.e. gender, age, T stage, and
three molecular indicators) cox regression analysis using
SPSS 21 to determine the independent prognostic factors.
Results
Landscape of gene expression profile of UTUC
We carried out gene expression profiling using digital
gene expression (DGE) sequencing in cancer and match-
normal tissues of renal pelvis from 10 patients with
UTUC (Additional file 1: Table S1). We first examined the
numbers of genes detected under different sequencing
depths, gene numbers (ranging from 15,874 to 17,546) al-
most saturated when the clean tag number was up to four
millions (Additional file 2: Figure S1), our sequence data
therefore is capable of detecting nearly all the transcribed
genes in our samples. From 14,833 to 16,605 expressed
genes were detected in 10 patients, and summaries of
mapping results were shown in Additional file 1: Table S3.
By comparing the mRNA expressions in cancer and
matched normal tissues, we identified from 3431 to 7702
significantly deregulated genes (fold >1 and FDR <0.1%)
across the 10 patients (Figure 1A). Besides, 5231 mRNAs
were recurrently deregulated (at least five cases, and aver-
age fold >1, Additional file 1: Table S4), of which 3248 and
1983 were up- and down-regulated, respectively. Differen-
tial expression analysis using similar pipeline was validated
by qPCR with the successful rate of ~88% [13]. In our
study, the expression patterns of 94 of the 100 gene × pa-
tient pairs from qPCR were consistent with sequenced re-
sults (Figure 1B), which demonstrated the high reliability
of our analytical pipeline.
To examine the pathway perturbations in UTUC, We
subjected all the recurrently deregulated genes to
ClueGO for pathway enrichment [19]. As shown in
Additional file 1: Table S5, significantly disrupted path-
ways (corrected *P <0.05) were distributed mainly in two
functional categories. Cell proliferation-related pathways
(e.g. p53 signaling and cell cycling, etc.) were up-
regulated. Interestingly, we also identified many metabolic
pathways like PPAR signaling pathway, and Glycine serine

















































































Figure 1 Number of differentially expressed genes (DEGs) in
each patient and qPCR validation of differential expression.
A, Number of up-regulated (red) and down-regulated (green) genes
in each patient. B, Log2ratio determined by sequencing analysis
(DGE, black) and -ΔΔCT value from quantitative PCR (qPCR, grey) are
shown (mean ± S.D.).
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the metabolic abnormalities in UTUC as observed in clear
cell renal cell carcinoma (ccRCC) [9,13].
Expression profile of UTUC possesses both shared and
tumor-specific molecular features compared to UC
of bladder
Current knowledge of UTUC is often based on the studies
of bladder UC [2,3]. However, studies have revealed that
big differences exist regarding clinical behaviors and even
molecular biology between the upper and the lower urin-
ary tract urothelial carcinoma [4,6-8]. We therefore com-
pared the expression profile of UTUC with that of bladder
UC published before [9]. We employed the same filtration
criteria to detect differentially expressed genes, and found
significant overlapping (***P <0.0001, hypergeometric test)
between these two datasets (Figure 2A), with 492 down-
regulated and 564 up-regulated genes were shared. We
next interrogated the functions of genes that were share,or specific in one of the two cancers. As shown in
Additional file 1: Table S5, genes commonly up- or down-
regulated in UTUC and bladder UC were mainly impli-
cated in pathways associated with cell proliferation. For
instance, Cell cycle and p53 signaling pathway were the
two most significant enriched pathways, and growth signal
transduction pathways like MAPK and PI3K-Akt signaling
pathways were significantly disrupted as well. Genes that
specifically dysregulated in UTUC were associated with
metabolic disorders (e.g. down-regulation of glycine,
serine and threonine metabolism and PPAR signaling
pathways). Genes specifically dysregulated in bladder UC
were associated with adhesion related pathways (e.g. Focal
adhesion and ECM-receptor interaction). These results
suggested both common and tumor-specific abnormalities
in UTUC and bladder UC.
We next performed hierarchical clustering with 1140
genes (Figure 2B) that were deregulated in both UTUC
and bladder UC. Although one UTUC was clustered
with bladder UCs, nine out of ten UTUCs were clus-
tered together as a distinct cluster. A subset of genes
were up-regulated in UTUCs but down-regulated in
bladder UCs (Figure 2B, top) though these two cancers
showed overall similar expression profiles. We also per-
formed hierarchical clustering with 372 genes (Figure 2C)
that were deregulated in UTUC, bladder UC as well as
ccRCC [9,13]. Interestingly, nine of ten UTUCs clustered
together as a distinct subcluster as in Figure 2B, and all
UTUCs were clustered with bladder UCs as a larger sub-
cluster being separated from cluster of ccRCCs. Taken
together, results shown above suggest that UTUC share
significant proportion of expression profile with bladder
UC, but these two cancers also characterized by tumor-
specific molecular features.
ALDH2, CCNE1 and SMAD3 are cancer relevant and
associated with overall survival in patients with UTUC
To identify the potential cancer-relevant genes in UTUC,
we performed leading edge analysis of GSEA to identify
the genes that are significantly aberrant in cancer path-
ways and correlative with cancer molecular [21]. The
resulting gene list included well-recognized tumor sup-
pressors and oncogenes like TP53, HRAS, PIK3CA and
CCND1. ALDH2, CCNE1 and SMAD3 were selected from
the list for further investigations because they were impli-
cated in the significantly disrupted pathways in UTUC.
CCNE1 and SMAD3 are implicated in the regulation of
cell cycling and growth signal transduction, while ALDH2
is a key player in multiple metabolic pathways. As shown
in Figure 3A, their mRNA expressions were significantly
different between cancer and match normal tissues of 22
patients with UTUC (***P <0.001, paired t-tests). We fur-
ther interrogated the functions of ALDH2, CCNE1 and
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Figure 2 UTUC possesses both shared and tumor-specific molecular features with bladder UC. A, Venn diagram shows the comparison of
deregulated genes in UTUC and bladder UC (BUC). The list of deregulated gene of UTUC is significantly overlapped with the deregulated genes
in bladder UC, with 492 down-regulated and 564 up-regulated genes were shared. B, Unsupervised hierarchical clustering of 1140 genes
deregulated in both UTUC and bladder UC. Both gene and sample clustering were done using average linkage and uncentered Pearson correlation
metric by Cluster 3.0, and results were visualized by TreeView. Hierarchical trees of gene clustering are not shown. C, Unsupervised hierarchical
clustering of 372 genes deregulated in UTUC, bladder UC as well as ccRCC. Analyses were done as described in B.
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shown in Figure 3B, Genes associated these three genes
were significantly enriched in G1/S (q-value <0.0001)
and G2/M (q-value <0.0001) transition of mitosis, and
regulation of TGF-β signaling pathway (q-value <0.001).
SMAD3, a part of TGF-β signaling, interacted with
other members (e.g. SMAD4, SKI and CDKN1C) in this
pathway. On the other hand, CCNE1 interplayed with
many other genes regulating the transition of mitotic
cell cycle (e.g. CDC25A, CDK2 and CDKN1C). ALDH2
co-expressed with CDKN1C, which was also interplay
with SMAD3 and CCNE1. Taken together, the deregula-
tion of CCNE1, SMAD3 and ALDH2 may lead to thedisruptions of cellular functions of cell cycle control,
tumor growth and metabolism.
To examine the prognostic roles of ALDH2, CCNE1
and SMAD3, we tested their protein expressions in FFPE
samples of cancer and adjacent normal tissues from 103
patients with UTUC (Additional file 1: Table S6) using
IHC assay. None of the patients underwent radiotherapy
or chemotherapy before surgery. As shown in Figure 3C,
CCNE1 and SMAD3 were strongly stained in the tumor
tissues but were weak in the normal tissues, whereas the
ALDH2 staining showed the reverse pattern. We then
dichotomized the 103 patients based on the protein ex-




















































Figure 3 ALDH2, CCNE1 and SMAD3 are significantly deregulated in UTUC and associated with cancer-relevant functions. A, qPCR
results of ALDH2, CCNE1 and SMAD3 in 10 patients in the discovery screen plus 12 independent cases. -ΔCT value normalized with U6 is
presented as mean ± S.D. to show the gene expression level in tumor and normal adjacent tissues. ***P <0.001, **P <0.01, *P <0.05, paired t-test.
B, Network of related genes of ALDH2, CCNE1 and SMAD3. Genes associated with ALDH2, CCNE1 and SMAD3 in terms of co-expression (blue lines),
pathway relationship (red), physical interaction (green), or sharing protein domain (purple) are identified using GeneMANIA. The thickness of the line
reflects the degree of association between two genes. The node size reflects how often paths start at the given gene node end up in one of the query
genes and how long and heavily weighted those paths are. And the node colors indicate down-regulation (green) or up-regulation (red) of the genes.
C, Representative IHC staining patterns for ALDH2, CCNE1 and SMAD3 in patients with UTUC and healthy people are shown (magnification 400X).
CCNE1 and SMAD3 were strongly stained in the cancer tissues but low in the normal tissues, whereas the ALDH2 was stained low in cancer tissues.
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tein expressions and clinicopathologic variables is shown
in Table 1. Low ALDH2, high CCNE1 and SMAD3 were
significantly associated with increase in tumor depth (T1,
T2 and T3; P <0.05, chi-square test). Interestingly, theirTable 1 Association between clinicopathologic variables
and molecular markers




Ta 0.015 0.027 0.034
Gender 0.823 0.819 0.492 0.712
aAssociation between tumor depth (T, including T1, T2 and T3 stages) and
protein expression and gender was calculated with chi-square test, other
p-values were calculated with Fisher’s exact test.expressions were also significantly correlated with each
other (***P <0.0001, Fisher’s exact test), low ALDH2
was associated with high CCNE1 and SMAD3. Next, we
examined the prognostic values of ALDH2, CCNE1 and
SMAD3 using Kaplan-Meier analysis. As shown in
Figure 4A-C, low expression of ALDH2 was signifi-
cantly associated with an adverse outcome, whereas
high CCNE1 and SMAD3 were associated with adverse
outcomes (all ***P <0.0001, log-rank test). In addition,
the predictive powers of ALDH2, CCNE1 and SMAD3
alone, and the combined marker (low ALDH2, high
CCNE1 and high SMAD3, Figure 4D) were similar,
which may in part be explained by their significant associ-
ations with each other (Table 1). In addition, multivariate
Cox-regression analysis indicated that the expressions of
ALDH2, CCNE1 and SMAD3 were independent diagnos-
tic indicators. Besides, we found that T1 patients had
***P < 0.0001 ***P < 0.0001















































































Figure 4 ALDH2, CCNE1 and SMAD3 are associated with overall survival in patients with UTUC. A-C, We dichotomized the 103 patients
based on the protein expressions, and evaluated the association of protein expression of ALDH2 (A), CCNE1 (B) and SMAD3 (C) with overall
survival rate using log-rank test. D, Different prognosis of patients with low (−) expression of ALDH2 and high (+) expression of CCNE1 and
SMAD3 (A-, S+, C+), and the remaining patients were shown. Mo: month.
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Hazard ratio =0.10), but we didn’t identify a significant
survival difference between T2 and T3 patients (Table 2),
which was also indicated by Kaplan-Meier analysis. Ex-
pressions of ALDH2, CCNE1 and SMAD3, however, were
able to identify the subgroup with higher mortality risk
within the patients in T2 and T3 stages (Additional file 2:
Figure S2). Further studies involving more patients will be
needed to confirm whether the molecular markers can
outperform the TNM staging in the outcome prediction
within the subgroup of patients in T2 and T3 stages.
Discussion
UTUC is an aggressive and heterogeneous cancer. And be-
cause of the rarity, comprehensive study on molecular basis
of UTUC is rare. To our knowledge, the present study is
the first exploration of genome-wide mRNA expression
patterns of UTUC using massively parallel sequencing.
Current knowledge of UTUC is mainly based on the
studies of bladder UC [2,3]. However, studies have sug-
gested that the clinical behaviors between the upper and
the lower urinary tract urothelial carcinoma can be dif-
ferent [4-6], UTUCs have a greater tendency towards
high-grade disease than bladder UCs [5,25,26]. Studies
of molecular insights also suggested the difference of
these two cancers. Catto et al. found that distinctpatterns of microsatellite instability and promoter methy-
lation of selected loci occur in these cancers [7,8].
Izquierdo et al. examined expressions of 13 genes relevant
to bladder UC in UTUC, nine of the genes showed signifi-
cant deregulations while four genes showed no significant
difference [27]. Moreover, none of these 13 genes were
correlated either tumor progression or survival in patients
with UTUC. Liang et al., however, identified that insulin-
like growth factor-binding protein-5 (IGFBP-5) was highly
up-regulated in both UTUC and bladder UC, and IGFBP-
5 was associated with advanced tumour stage and inferior
survival in both cancers. These studies together suggests
that there are shared and tumor-specific features between
UTUC and bladder UC. However, the conclusions by
above studies may be limited by the fact that only some
selected genes were examined. In the present study, we
compared the genome-wide expression patterns of UTUC
with those of bladder UC, and found that these two cancer
share large proportion of expression profile, which are
consistent with a published study investigating the ex-
pression profiles of UTUC and bladder compared to
healthy individuals using microarray [28]. Using hier-
archical clustering of expression profiles, the authors
found that UTUCs and bladder UCs were clustered
together being separated from healthy controls [28].
The authors also identified a small subset of genes
Table 2 Cox regression analyses for determining outcome based on the expression of ALDH2, CCNE1 and SMAD3
Variables No. patients Univariate Multivariate
p-valuea HR (95% CI) p-valueb HR (95% CI)
Sex
Female 26 0.98 0.99 (0.39-2.51) 0.92 1.05 (0.40-2.73)
Male 77
Age 32-87 years 0.96 1.00 (0.96-1.04) 0.97 1.00 (0.96-1.04)
T stage
T1 62 7.32 × 10−06 0.10 (0.03-0.27) 7.27 × 10−06 0.09 (0.03-0.27)
T2 16 0.12 0.413 (0.14-1.26) 0.12 0.41 (0.13-1.26)
T3 25
ALDH2
Low 54 1.69 × 10−04 52.02 (6.63-407.94) 2.11 × 10−04 81.91 (7.96-842.24)
High 49
CCNE1
Low 59 4.53 × 10−04 41.4 (5.17-331.66) 6.38 × 10−04 36.27 (4.24-309.92)
High 44
SMAD3
Low 62 9.51 × 10−04 31.14 (4.05-239.33) 1.04 × 10−03 61.90 (5.80-660.64)
High 41
aP-value and hazard ration (HR) were calculated for each variable using Cox regression model. Sex: female vs. male; Age: continuous variable and range of age is
shown instead of number of patients; T stage: T1 vs. T3, T2 vs. T3; ALDH2: low vs. high; CCNE1 and SMAD3: high vs. low. bP-value and HR of each molecular marker
were adjusted for clinicopathological factors and determined separately with Cox regression model.
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bladder UC. In our study, we found that, compared to
bladder UC, UTUC is characterized by abnormalities in
metabolic pathways, which was also observed by our
group in ccRCC [9,13]. Interestingly, kidney cancer has
been suggested as a metabolic disease, many kidney cancer
genes like VHL, MET and TSC1/2 are involved in
metabolism-related pathways [29]. Our results suggest
that metabolic disorder may be an important specific fea-
ture of UTUC compared to bladder UC.
Previous surveys of molecular prognostic indicator for
UTUC were usually based on some pre-selected genes,
tumor stage and grade still represent the best-established
prognostic indicators [3,4]. In our study, ALDH2, CCNE1
and SMAD3 were selected for further investigation based
on the results of global expression profiling. All these
three genes were significant and independent prognostic
indicators in patients with UTUC. Our data also suggested
that these molecular markers may be more robust in iden-
tifying the patient subgroup with higher mortality risk
than the TNM staging, which may need to be confirmed
with further investigations. ALDH2 is one of the key me-
diators in the disrupted metabolic pathways in our study.
One of its functions is to break down acetaldehyde metab-
olized from ethanol, inhibition of ALDH2 therefore may
result in the build-up of acetaldehyde, which is a highly
toxic and carcinogenic compound [30]. Downreglation ofALDH2 has also been reported in lung cancer, and
ALDH2 interacting with alcohol drinking are risk factors
of stomach cancer [31,32]. Previously, prognostic markers
associated with the functions of cell cycle, proliferation,
differentiation, apoptosis, and cell adhesion were evaluated
in UTUC [4], our results suggested that gene associated
with metabolic abnormalities could also be potential tar-
gets for developing new prognostic and therapeutic ap-
proaches for patients with UTUC.
SMAD3 is a key mediator of TGF-β signaling pathway
regulating tumor growth and metastasis, and overex-
pression of SMAD3 was also detected in prostate cancer
[33]. Other signaling transduction molecular like EGFR
had been suggested as prognostic indicator in patients
with UTUC [4], but the present study revealed the prog-
nostic value of SMAD3 in UTUC for the first time.
CCNE1 has been reported as an independent, unfavor-
able prognostic indicator in breast and Non-Small Cell
Lung cancer [34,35]. This gene is important for G1-S
cell cycle control, it binds to and activates the Cdk2, and
then accelerates the cell enter into S phase and achieves
unrestricted tumor growth [36]. Several other cell-cycle
related prognostic markers like p53, SKP2 and CKS1 for
UTUC have been reported [37,38]. Interestingly, all of
p53, SKP2 and CKS1 could regulate the inactivation or ac-
tivation of cyclin E-Cdk2 via mediating p21/p27. CCNE1
therefore may also represent a promising prognostic
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more in-depth studies will be needed to elucidate the roles
of ALDH2, CCNE1 and SMAD3 in UTUC.
Conclusions
We in this study examined the genome-wide expression
profile of UTUC, pathway enrichment suggested that ex-
pression patterns of UTUC are characterized by abnormal-
ities in cell proliferation, and metabolism representing a
UTUC specific feature compare to bladder UC. Import-
antly, we, for the first time, revealed that the protein ex-
pressions of ALDH2, CCNE1 and SMAD3 were significant
and independent prognostic markers for patients with
UTUC, which may facilitate the clinical management of
this cancer.
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